Head and Neck Cancer

Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval

By

Brian Park, PharmD

Publish Date August 16, 2019

The Food and Drug Administration (FDA) has granted accelerated approval to Rozlytrek (entrectinib; Genentech)

Factors Associated With Thyroid Cancer Overtreatment Identified

Publish Date July 26, 2019

Overtreatment more likely in younger, male, Hispanic or Asian patients, those with extensive lymph node surgery.

Pediatric Thyroid Cancer Rates Are Rising, but Some Experts Doubt the Significance

By

Jessica Wapner

Publish Date July 9, 2019

The increased prevalence may be real, or it could be the result of the detection of more harmless tumors through increased screening efforts.

The Effect of Concurrent Implementation of a Nurse Navigator and Pretreatment Care Map on Time to Treatment for Head and Neck Cancer Patients

By

Carolyn Ruffing, BSN, RN, MS, OCN

Paul Van Der Sloot, MD

Publish Date June 13, 2019

Researchers report on implementation of a nurse navigator and pretreatment care plans on time from diagnosis to treatment for patients with head and neck cancers.

ASCO: Low-Dose Chemotherapy Benefits Advanced Gastroesophageal Cancer

Publish Date June 10, 2019

Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity.